In this episode of Baptist Health’s Doc-to-Doc, we take a closer look at one of the most concerning trends in oncology — the rise of breast cancer among younger women.

Dr. Anastasia Tousimis, Deputy Director of Baptist Health Cancer Care, sits down with Dr. Louise Morrell, Chief Medical Executive of Lynn Cancer Institute, to discuss what’s driving this gradual increase and how clinicians can better identify, screen and support high-risk patients.

Together, they explore the latest research on environmental and genetic factors, screening challenges in dense breasts and how AI is transforming early detection. The discussion also highlights fertility preservation and the importance of multidisciplinary care for young women navigating a diagnosis.

From radiation exposure to BRCA mutations, this conversation connects cutting-edge science with compassionate care — offering practical insight for clinicians and reassurance for patients alike.

Host:
Anastasia Tousimis, M.D.
Deputy Director, Baptist Health Cancer Care
Medical Director, Al and Jane Nahmad Women's Cancer Center, Baptist Health

Expert:
Louise Morrell, M.D.
Chief Medical Executive
Eugene M. & Christine E. Lynn Cancer Institute
Baptist Health Boca Raton Regional Hospital

In this Baptist Health Doc-to-Doc episode, Dr. Michael McDermott, Chief Medical Executive of Baptist Health Miami Neuroscience Institute sits down with Dr. Evan Bander, Neurosurgeon & Co-Director of the Pituitary Tumor Program at the Baptist Health Miami Neuroscience Institue, to unpack the complexities of the body’s “master gland.”

Together, they explore how pituitary tumors are diagnosed and treated, the difference between functional and non-functional adenomas and why minimally invasive endoscopic surgery is changing outcomes. You’ll hear about early warning signs such as vision changes, the importance of a multidisciplinary pituitary team and the latest surgical and radiosurgical approaches. Whether you’re a clinician managing these conditions or a patient seeking to better understand them, this discussion sheds light on earlier detection, safer surgery and lifelong follow-up.

👉 If you are a neurosurgeon, endocrinologist, or ENT specialist managing pituitary disorders, this conversation will help sharpen your clinical edge.
👀 Patients and families can also learn what to look for and what today’s treatment options mean for long-term health.

🔔 Subscribe for more expert insights: @BaptistHealthSF

Host:

Michael McDermott, M.D.
Chief Medical Executive and Irma & Kalman Bass Endowed Chair in Clinical Neuroscience at Miami Neuroscience Institute, as well as Chair of the Department of Neurosciences at Florida International University Herbert Wertheim College of Medicine

Expert:

Evan Bander, M.D.
Neurosurgeon & Co-Director of the Pituitary Tumor Program
Baptist Health Miami Neuroscience Institute

In this episode of Baptist Health's Doc-to-Doc, we explore the evolving landscape of arrhythmia care with host Tom Nguyen, M.D., Chief Medical Executive of Baptist Health Heart & Vascular Care, Director of Minimally Invasive Surgery, and Barry T. Katzen Endowed Chair at Miami Cardiac & Vascular Institute, and Professor and Chair of the Department of Cardiovascular Sciences at Florida International University Herbert Wertheim College of Medicine. Electrophysiologist, Mario Pascual, M.D., and Cardiothoracic surgeon, Bryon Tompkins, M.D. of Baptist Health Heart & Vascular Care.

Together they discuss why early referral changes AFib outcomes, how hybrid epicardial-endocardial ablation strategies improve rhythm durability and the role of left atrial appendage management in reducing stroke risk. The conversation also highlights modern pacing approaches to protect heart function, the importance of timely device infection management and the emerging impact of Al and robotic mapping on electrophysiology and surgical collaboration.

👉 If you are a cardiologist, electrophysiologist or cardiac surgeon navigating the complexity of rhythm disorders, this conversation will help sharpen your clinical edge.

🔔 Subscribe for more expert insights: @BaptistHealthSF

Tom Nguyen, M.D.
Cardiac Surgeon & Chief Medical Executive
Baptist Health Heart & Vascular Care
Chair, Cardiovascular Sciences, FIU

Mario Pascual M.D.
Electrophysiologist
Baptist Health Heart & Vascular Care

Bryon Tompkins, M.D.
Cardiac Surgeon
Baptist Health Heart & Vascular Care

In this episode of Doc to Doc, we explore groundbreaking advances in the treatment of blood cancers with two of the field’s leading experts:
Dr. Guenther Koehne, Deputy Director and Chief of Blood and Marrow Transplant, Hematologic Oncology and Benign Hematology, and Dr. Firas El Chaer, Chief of Leukemia Services and Medical Director of Infusion — both from Baptist Health Miami Cancer Institute.

From precision-targeted therapies and measurable residual disease (MRD) to cutting-edge immunotherapies like (CAR) T-cell therapy, BiTEs, and NK-cell approaches — we cover the evolving tools that are reshaping treatment protocols across leukemia, myeloma, MDS, and lymphoma.

Topics Covered:
✅ MRD-guided treatment decisions
✅ Overcoming drug resistance with combination strategies
✅ Targeted therapies for actionable mutations
✅ The expanding role of CAR T, BiTEs, and NK cells
✅ Clinical application and access at Baptist Health

If you're an oncologist, hematologist, or transplant specialist navigating the complexity of hematologic malignancies — this conversation will help sharpen your clinical edge.

🔔 Subscribe for more expert insights: @BaptistHealthSF
📍 Learn more at MiamiCancerInstitute.com

Why do thyroid cancers demand a more nuanced approach, despite high survival rates?

In this episode of Doc to Doc, Dr. Meghan Crawley, head and neck surgical oncologist at Miami Cancer Institute, joins Dr. Rachel Slotcavage, endocrine surgeon at Lynn Cancer Institute, to explore what makes thyroid cancers so unique and how treatment approaches are evolving.

From surgery and RAI therapy to targeted therapies, immunotherapy, and biomarker-driven decisions, this conversation takes a closer look at how precision medicine is shaping the future of thyroid cancer care—and what every clinician should consider in today’s multidisciplinary landscape.

Meghan Crawley, M.D.
Head and Neck Surgical Oncologist with Baptist Health Miami Cancer Institute

Rachel Slotcavage, M.D.
Endocrine surgeon with the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital

What happens when landmark trials challenge long-standing surgical standards?

In this episode of Doc to Doc, Dr. Thomas Morrissey, director of gynecologic oncology at Lynn Cancer Institute, joins Dr. Ryan Kahn, gynecologic oncologist at Miami Cancer Institute, to explore how data from pivotal studies like TRUST, SHAPE, and MIRASOL are redefining treatment decisions in gynecologic cancer.

From respectability scoring to the evolving role of checkpoint inhibitors and targeted antibody-drug conjugates, this conversation highlights a bold shift toward more personalized, evidence-based care, and what every clinician should know in this new era.

Thomas Morrissey, M.D., Director of Gynecologic Oncology with the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital.

Ryan Kahn, M.D.
Gynecologic Oncologist
Baptist Health Miami Cancer Institute

What happens when we stop gatekeeping genetic testing and offer it universally?

In this episode of Doc to Doc, Dr. Arelis Martir Negron, medical geneticist at Miami Cancer Institute, joins Dr. Venkatappa to explore how the field of cancer genetics is transforming — and what every clinician should know. From BRCA1 and BRCA2 to multi-gene panels and AI-powered risk stratification, testing this conversation covers the past, present, and bold future of universal germline testing.

Host:

Siddhartha Anantha Venkatappa, M.D., Oncologist/Hematologist at Baptist Health Miami Cancer Institute

Guest:

Arelis Martir Negron, M.D., FAMG, Medical Geneticist at Baptist Health Miami Cancer Institute

Brain tumors remain among the most complex and challenging conditions we confront. There are over 120 histologically distinct tumor types, with survival outcomes varying drastically depending on molecular profile and location. As a result, the need for nuanced, multidisciplinary care has never been more evident.

While advances in neuroimaging, genomic profiling, and immunotherapy have shifted paradigms, many patients still face limited treatment options and high morbidity.

During Brain Tumor Awareness Month, we’re reinforcing our shared commitment to early detection, clinical trials, patient-centered research, and the ethical complexities of surgical and systemic interventions.

From glioblastomas to benign meningiomas, and from pediatric to geriatric cases, we’ll be spotlighting emerging data, revisiting case studies, and discussing how to translate innovation into outcomes.

Presenters:

Manmeet Ahluwalia, M.D., MBA, FASCO, Chief Scientific Officer, Chief of Medical Oncology, Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute

Minesh P. Mehta, M.D., Chief of Radiation Oncology, Deputy Director and John and Mary Lou Dasburg Endowed Chair in Radiation Oncology at Baptist Health Miami Cancer Institute